Doctor David Samadi – Inventor Of The SMART Robotic Technique

Doctor David Samadi was born in Iran in the Persian Jewish nation where he grew up. In 1979 Samadi left Iran. He attended Stoney Brook University, where he received a biochemistry degree. He graduated from Stony Brook School of Medicine, New York as an M.D. in 1994. Dr. David Samadi received his postgraduate education in urology at Montefiore Medical Center. In 1996, he received his training in Proctology from Albert Einstein College of Medicine. While attending Memorial Sloan Kettering Cancer Center he finished his oncology fellowship in Proctology.

What Is The SMART Robotic Technique?

The SMART Robotic Technique was developed by Dr. David Samadi in treating cancer of the prostate. Instead of performing open surgery for prostate cancer, this less invasive method along with the DaVinci Surgical approach is better. Dr. Samadi is an expert in the medical field of diagnosing and treating Urologic diseases and cancer of the prostate. Using the SMART and DaVinci robotic surgery the results are great leaving the patient’s recovery time less than with the traditional method. This method leaves almost no scarring.

Dr. Samadi TV Began September 2017

Dr. Samadi Sunday Housecall TV answers questions on prostate health. He stresses the importance of getting screened for early detection and treatment. Dr. Samadi TV airs each Sunday beginning at 12:30 – 1:30 p.m. EST. He is seen on Facebook, Twitter, and YouTube live. He uses social media to reach a wider audience.

Awards Received By Dr. Samadi

During his distinguished career, Dr. Samadi received many awards, which included the Vitals Patients’ Choice Award, which he received in 2008 – 2014.In 2014, he was given the New York Super Doctors award. In 2010 – 2011 Dr. Samadi received the Most Compassionate Doctor awards. In 2009-2012 and 2015 Dr. David Samadi received an award by New York Magazine as Best Doctor.

Dr. David Samadi’s Comment On Mitt Romney’s Prostate Cancer

Mitt Romney was diagnosed with prostate cancer and underwent prostate surgery. Dr. Samadi believes that Mitt Romney’s projected outlook after having prostate surgery was good.

Dr. David Samadi’s Interview by Ideamensch

During the interview of Dr. Samadi had with Ideameasch he was asked about his day at work. Dr. Samadi stated that he woke up in the mornings at 4:30 a.m. and arrives at his office at 6:00 a.m. He spends a productive hour and a half at the office before performing two to three surgeries every week.

Cancer Treatment Centers Of America Teams Up For Men’s Health

Prostate cancer is regularly diagnosed in men of all ages. In order to spread awareness of regular testing and education of this deadly disease, Cancer Treatment Centers of America (CTCA) is paring up with LabCorp and the National Football League Alumni Association (NFLA) to bring a series of events named “Prostate Pep Talk” to each of the CTCA’s locations featuring alumni and current players of the NFL. These events are designed to raise awareness that regular testing and education is necessary to optimal prostate health.

Along with the educational events, LabCorp is offering free screenings to the first 2,000 men who signed up for a PSA (Prostate Specific Antigen) test. PSA testing can indicate an anomaly within the prostate if testing comes back abnormal. When the 2,000 spots get filled up, LabCorp is offering a low cost fee of $25.00 for the PSA to be performed. Patient’s need to schedule the test within six months to still be eligible for the free or reduced price spots.This latest joint venture is a sign of CTCA’s commitment to patient care excellence.

Based in Boca Raton, Florida, CTCA has been offering cutting edge cancer care to it’s patients across the nation. There are five current facilities: Philadelphia, Atlanta, Chicago, Tulsa, and Phoenix that make the same commitment to treat the patient as a whole being: mind, body, and soul.CTCA offers the best in treatments including: precision cancer treatment, surgery, immunotherapy, chemotherapy, radiation, and genome testing. CTCA takes care of their patients from day one, offering supportive therapies for those going through treatment. CTCA even provides aftercare when a patient has completed their cancer treatment program. To read more about CTCA’s latest venture.

How Clay Siegall Is At The Forefront of Cancer Research

As the co-Founder, President, Chief Executive Officer, and Chairman of the Board of Seattle Genetics, Inc., Clay Siegall is at the forefront of cancer research. Seattle Genetics is a company, headquartered in Bothell, Washington, that creates cancer drugs using antibody-drug conjugates. Ever since the release of the drug Adcetris, which treats lymphoma and potentially other types of cancers, in 2012 the company’s stock has tripled in value.

Dr. Siegall has exhibited a passion throughout his career for helping patients that are suffering from cancer. He is a graduate of George Washington University where he earned his Ph.D. in Genetics. He began his professional career at Bristol-Myers Squibb Pharmaceutical Research Institute as a Senior Research Investigator. He was promoted to Principal Scientist during his time at this institute. He has also performed research at the National Cancer Institute where he was a Staff Fellow and Biotechnology Fellow.

Helping cancer patients and diligently performing scientific research lies at the heart of Dr. Clay Siegall’s career. His cancer drug, Adcetris, is now being used in 60 countries and has helped saved many thousands of lives. He also has several more cancer drugs in the pipeline and is researching Adcetris’s promising potential to cure more types of cancer.

Due to Dr. Siegall’s leadership, Seattle Genetics has raised over $1.2 billion in funding from both the public and private sectors. This money has been used to hire more research staff, pay for more drug styles, and used to acquire the latest lab technology.

Dr. Siegall’s depth of knowledge and acumen has led to his acquiring 15 patents and having more than 70 scientific articles published.

As the leader of Seattle Genetics, Clay Siegall is responsible for the day-to-day operations of the company. He also is responsible for developing strategic partnerships with other companies. With Adcetris, Seattle Genetics markets and distributes it in the U.S. and Canada while Takeda Pharmaceutical Company does the same in the rest of the world. Dr. Siegall has also formed relationships with other companies such as Genentech, Pfizer, Abbvie, and GlaxoSmithKline.